Explore more publications!

Beauty Press Releases: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Beauty Press Releases.

Press releases published on December 6, 2025

Dr. B Dental Solutions Rises as Top Contender in the Silver Economy as Denture Care Demand Surges in the U.S.
ThinkCareBelieve:  Week 46 America Shining Brightly
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
Sapu Nano 宣布推出基于 Deciparticle™ 技术的生物标志物框架,用于识别最可能对静脉注射 Sapu003(一种依维莫司纳米药物)产生反应的肿瘤
Sapu Nano 宣佈由 Deciparticle™ 驅動的生物標記框架,可識別出最有可能對靜脈注射依維莫司納米藥物 Sapu003 產生反應的腫瘤
Roofing Expert Keith Miller Clarifies Why Flashing Is the Source of Many Roof Leaks in HelloNation
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
DeFi Crypto Mutuum Finance Prepares for 20% Price Increase as Phase 6 Nears Completion
New Crypto Coin Mutuum Finance Nears 100% of Phase 6 Allocation as Price Shift Approaches
Sapu Nano 公布新的药代动力学数据显示,与口服给药相比,静脉注射 Sapu003 可将依维莫司的胃肠道积累量减少 67 倍
Sapu Nano 發表最新藥物動力學數據,顯示與口服劑量相比,靜脈注射 Sapu003 可將積聚在腸胃的依維莫司 (Everolimus) 量降低達 67 倍
Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinson’s Disease

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions